Sarepta Therapeutics says it has been informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company’s gene therapy for Duchenne muscular dystrophy (DMD). Sarepta said its investigation indicated the report was not submitted by its employee or the study’s principal investigator. The drug safety monitoring board has recommended the study to continue after a review, the company said in a statement. For its part, the US FDA says that it is looking into the matter but does not have any new information at the time of this writing. Learn More